Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94228Research ArticleApproaches to the choice of a statin to treat patients on an outpatient basisOstroumovaO. Dostroumova.olga@mail.ruDudaevV. A-SchukinaG. N-A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian FederationI.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation15012015171444928122021Copyright © 2015, Consilium Medicum2015The paper presents an algorithm of examination of the patient to decide on the appointment of statins for the treatment of dyslipidemia and atherosclerosis. The criteria of the effectiveness of statin therapy. The advantages of atorvastatin and rosuvastatin. We discuss the choice of a statin for the treatment of selected patients with changes in blood lipid spectrum.dyslipidemiaatherosclerosisatorvastatinrosuvastatingenericsдислипидемияатеросклерозаторвастатинрозувастатингенерики[Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012; 4 (9): 2-52.][Клиническая фармакология. Под ред. В.Г.Кукеса. М.: ГЭОТАР-Медиа, 2008; с. 648-65.][Sever P.S, Dahlof B, Poulter N.R et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.][La Rosa J, Grundy S.M, Waters D.D et al. For the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425-34.][Cannon C.P, Braunwald E, Mc Cabe C.H et al. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Eng J Med 2004; 350: 1495-504.][Colhoun H.M, Betteridge D.J, Durrington P.N et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo - controlled trial. Lancet 2004; 364: 685-96.][Amarenco P, Bogousslavsky J, Callahan A 3rd et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High - dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.][Мухин В.П., Жиляева Ю.А. Дженерические статины в клинической практике: дешевые заменители или достойная альтернатива брендам. Аторвастатин. Архивъ внутр. медицины. 2012; 2 (4): 72-6.][Ridker P.M, Darielson E, Fonseca F.A et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21): 2195-207.][Jones P.H, Davidson M.H, Stein E.A et al and STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.]